Vertex Pharma (VRTX) Misses Q4 EPS by 8c, Revenues Beat; Provides FY21 Product Revenue Outlook
Get Alerts VRTX Hot Sheet
Revenue Growth %: +8.9%
Financial Fact:
Total costs and expenses: 432.51M
Today's EPS Names:
RUSHA, SEIC, OSBC, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $2.51, $0.08 worse than the analyst estimate of $2.59. Revenue for the quarter came in at $1.63 billion versus the consensus estimate of $1.58 billion.
"Our achievements in 2020 were marked by a significant increase in the number of people treated with the triple combination in the U.S. and the EU. It was also a year marked by meaningful pipeline advancement. We now have clinical programs in seven disease areas, spanning multiple modalities including small molecules for alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases, gene editing for sickle cell disease and beta thalassemia, and cell therapy for type 1 diabetes,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. "As we enter 2021, we look forward to treating more CF patients and reaching important R&D milestones in multiple additional diseases which will fuel our growth this year and for many years to come."
GUIDANCE:
Vertex Pharma sees FY2021 revenue of $6.7-6.9 billion, versus the consensus of $6.95 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amphenol (APH) Tops Q1 EPS by 7c, offers guidance
- Apollo's (APO) ATLAS SP Announces Investment from MassMutual
- Farmers National Banc (FMNB) Tops Q1 EPS by 1c
Create E-mail Alert Related Categories
Corporate News, Earnings, Guidance, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!